Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

http://www.wikidata.org/entity/Q43584641

about

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Relapsed Hodgkin lymphoma: management strategies Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.Bendamustine: role and evidence in lymphoma therapy, an overview.Classical Hodgkin's lymphoma: past, present and future perspectives.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Hodgkin's Lymphoma in Older Patients: an Orphan Disease?Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma.Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

P2860

Q33420273-B3D2F46D-C457-476C-9677-B0732FE9BE4A Q37008427-1780A456-399E-4559-A2DC-9E097A643130 Q37029856-2B66E06B-AEF9-4DEA-B0B7-467B72287937 Q38158084-90D27CF9-859D-460C-B3C2-D2DF8651C3F7 Q38162057-4707DE80-3859-4E97-B197-1513C93C63F8 Q38179975-EB836DC1-F3FF-4D29-96FC-2C79FD86EC18 Q38232075-E7FD2161-4241-48CA-9A70-1B4FE141918B Q38368587-5D996B6F-B4CD-4292-885B-6C2C3E8D8555 Q38466376-1ACE88D1-3935-41F7-8165-3397B4AFFFA4 Q38642648-C8D2132F-CF0B-4BA6-A647-462C96DC4DD0 Q38700745-30E06A0C-5B11-4F24-A035-52B29D994449 Q39005626-7398EC18-A85C-443E-9A78-F95F9C994DF3 Q39974781-35CD557B-371A-4D89-9617-516D41D9C871 Q40979223-B313A145-65FF-4D3A-9D8B-55332066E9F8 Q42375641-27F33C29-884C-402A-948F-4DFBB1F580E9 Q42384513-5CD230C6-CB80-4D84-946B-0D1229C8CE0D Q46698290-5F9CFE0F-D162-4188-8011-1E10F1F0F163 Q48146418-41906C43-F7EA-4F6B-A666-7466C6B909BE Q52779365-31193616-B8A5-4AC9-89BF-64EA0BBC4B3A Q58766568-BC4D44DA-ECD7-421E-9C07-390055E1CE5B Q58924276-849E3C7E-B257-4FAB-B8EB-6D461C76B387

P2860

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

http://www.wikidata.org/entity/Q43584641

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Efficacy and safety of bendamu ...... th recurring Hodgkin lymphoma.

@en

Efficacy and safety of bendamu ...... th recurring Hodgkin lymphoma.

@nl

type

label

Efficacy and safety of bendamu ...... th recurring Hodgkin lymphoma.

@en

Efficacy and safety of bendamu ...... th recurring Hodgkin lymphoma.

@nl

prefLabel

Efficacy and safety of bendamu ...... th recurring Hodgkin lymphoma.

@en

Efficacy and safety of bendamu ...... th recurring Hodgkin lymphoma.

@nl

P1433

Q43584641-FC6B5B51-5485-4335-A3F6-10E83ABDA7D1

P1476

Q43584641-543375EA-C299-4AE0-8A82-E9DB24513A14

P2093

Q43584641-0B16A21D-2783-4F39-ACF0-56166D286BC3

Q43584641-0D02C074-33E7-4796-BE21-40FC412D810C

Q43584641-23203789-7C06-4E73-9585-6A387C99A101

Q43584641-39AB3596-C780-42AB-84D5-60C3695B1B96

Q43584641-3C0F608D-1342-4E8A-B0AE-2C2DDFE6A395

Q43584641-62376061-DB04-4B8B-AC1D-5D4F97A489EB

Q43584641-6C4A96E1-2DF2-47A5-8C60-5CED2DA80C40

Q43584641-96CBCEEF-D9F0-44AB-97E9-ECF7BC134DA5

Q43584641-A5EE9DAA-2231-4D35-AC64-58A4F77291B4

Q43584641-CAB0C9A3-1B45-4101-B3D3-6091C6453FC6

P2860

Q43584641-082281BB-2C5E-40B3-83C2-EC2E7EC9F277

Q43584641-1D6096D6-A779-4DEE-A5F9-393DE1B81134

Q43584641-241F2628-D83B-4C5B-BAAF-FBAB395ABDFD

Q43584641-2B9E6F70-7EB3-4C3D-ACF5-2E718F5BC85B

Q43584641-42CEDF00-51DA-443D-8C2F-41818A9B9791

Q43584641-4D026C7E-81F9-4DCD-8BFE-53ECF1B128F2

Q43584641-51A5955F-6067-4E03-82BE-3F219F7068D5

Q43584641-5237E65E-B507-46C6-974D-B103DEE19936

Q43584641-557B6559-9EF4-4D38-A50E-ED2B7D687A6F

Q43584641-60FA0886-6EE7-4090-AA66-C1AB5E9CA0C1

P304

Q43584641-4C76D7A7-2A37-43B9-AD3F-054BF4208983

P31

Q43584641-BFE04935-781B-474C-B72A-F1179836DF89

P356

Q43584641-7AD6155C-A49D-4E5B-A232-B673455E012D

P407

Q43584641-7D47DC2A-671F-4E63-B945-BEFCBA4A2752

P433

Q43584641-A7FBB1B2-7BA3-4EB6-8388-00F8C96632B5

P478

Q43584641-68AF9377-007F-42C5-81D7-986A942A0473

P50

Q43584641-27D6B736-0159-46CB-A01E-14A4CEC52F03

Q43584641-3E8406FE-09D2-4348-9F11-055BD5ED635F

Q43584641-EB1D8B8F-D94A-475B-B77C-9C4E053808E9

Q43584641-EBB822D5-332D-47BB-8D9F-4F54FF801F02

P577

Q43584641-3EDA24A5-5D78-4577-BBB2-467FBA9DF65F

P5875

Q43584641-BBC0CFA5-EF5E-4480-8025-34D2128AE036

P698

Q43584641-ED88DA0D-9231-4B72-A0CB-274C669D360D

P356

P1433

British Journal of Haematology

P1476

Efficacy and safety of bendamu ...... ith recurring Hodgkin lymphoma

@en

P2093

Alfonso D'Arco

http://www.w3.org/2001/XMLSchema#string

Antonio Pinto

http://www.w3.org/2001/XMLSchema#string

Catello Califano

http://www.w3.org/2001/XMLSchema#string

Caterina Stelitano

http://www.w3.org/2001/XMLSchema#string

Emilio Iannitto

http://www.w3.org/2001/XMLSchema#string

Felicetto Ferrara

http://www.w3.org/2001/XMLSchema#string

Francesco Angrilli

http://www.w3.org/2001/XMLSchema#string

Gaetano Corazzelli

http://www.w3.org/2001/XMLSchema#string

Manuela Arcamone

http://www.w3.org/2001/XMLSchema#string

Rosaria De Filippi

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Bendamustine: rebirth of an old drug.

State-of-the-art therapeutics: Hodgkin's lymphoma.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Salvage therapy in Hodgkin's lymphoma.

Novel small-molecule therapy of Hodgkin lymphoma.

P304

207-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12120

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

160

http://www.w3.org/2001/XMLSchema#string

P50

Pellegrino Musto

M Christina Cox

Attilio Guarini

P577

2012-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233736553

http://www.w3.org/2001/XMLSchema#string

P698

23167437

http://www.w3.org/2001/XMLSchema#string